AstraZeneca I8D-MC-AZES
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety,
Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer’s Disease (The
AMARANTH Study)
